Positive Phase III top-line results for Endo/BDSI pain drug; milestone triggered
This article was originally published in Scrip
Executive Summary
Endo Pharmaceuticals and BioDelivery Sciences' (BDSI) have released positive top-line Phase III data for chronic pain drug BEMA buprenorphine, triggering a $10m milestone payment to the latter firm.